James Barclay and Barclay Capital Consult Sees Massive Success with Bet on French Biopharmaceutical Company Cellectis SA

Nov 2, 2023

Key Takeaways

  • James Barclay and his private equity firm, Barclay Capital Consult, have been longstanding supporters of Cellectis SA, a prominent French biopharmaceutical company.
  • The stock of Cellectis SA surged by over 170% in Wednesday's trading session, showcasing the remarkable results of James Barclay's investment strategy and belief in Event Driven Investing.
  • Event Driven Investing is an approach that capitalizes on specific events and catalysts to generate substantial returns on investment.
  • Cellectis SA, known for its innovative approaches to gene editing and cellular therapies, has great potential in the biopharmaceutical sector and Barclay's investment has played a pivotal role in realizing this potential.
  • Barclay Capital Consult's success with the Cellectis SA investment further establishes the firm as a leader in private equity and event-driven investments.

James Barclay, a seasoned investor, and his private equity firm, Barclay Capital Consult, have been longstanding supporters of Cellectis SA, a prominent French biopharmaceutical company.

London, England, United Kingdom - November 2, 2023 /PR Fire/ —

James Barclay, a seasoned investor, and his private equity firm, Barclay Capital Consult, have been longstanding supporters of Cellectis SA, a prominent French biopharmaceutical company. Their steadfast faith and commitment to Cellectis SA have yielded remarkable results, with the stock surging by over 170% in Wednesday's trading session. This monumental achievement is a testament to their investment strategy and deep-rooted belief in Event Driven Investing.

Event Driven Investing is an approach that capitalizes on specific events and catalysts to generate substantial returns on investment. James Barclay, the driving force behind this investment strategy, has dedicated years of hard work and expertise to bring these significant gains to his clients and firm. He expressed his excitement about this remarkable success, saying, "I am delighted for my clients as well as my firm with these monumental profits we have shown. I see Event Driven Investing as an art, and it comes through years of hard work. I would like to give thanks to my analysts in New York and also to my clients who have held their nerve and trusted my forecasts that this fantastic company would show us some serious percentage gains."

Cellectis SA, a leading player in the biopharmaceutical industry, is renowned for its innovative approaches to gene editing and cellular therapies. The recent surge in the company's stock price underscores the outstanding potential of Cellectis SA in the biopharmaceutical sector. James Barclay's foresight and astute investment decisions have been pivotal in realizing the company's potential.

Barclay Capital Consult has gained a reputation for its commitment to providing investors with exceptional opportunities in the market. The success of the Cellectis SA investment further cements the firm's position as a leader in the world of private equity and event-driven investments.

James Barclay and Barclay Capital Consult continue to pursue promising opportunities, demonstrating their dedication to delivering value and returns to their clients. Their investment in Cellectis SA serves as a shining example of the firm's commitment to identifying and capitalizing on transformative events in the market.

Contact Info:
Name: James Barclay
Email: Send Email
Organization: Barclay Capital Consult
Website: https://www.barclaycc.com

Source: PR Fire

Release ID: 89112165

In the event of detecting errors, concerns, or irregularities in the content shared in this press release that require attention or if there is a need for a press release takedown, we kindly request that you inform us promptly by contacting [email protected]. Our dedicated team will promptly address your feedback within 8 hours and take necessary actions to resolve any identified issues diligently or guide you through the removal process. Providing accurate and dependable information is our utmost priority.

More News

Eala on track for Alexandrova, Fernandez rematch

Oct 11, 2026

Eala on track for Alexandrova, Fernandez rematch

FILIPINO sensation Alex Eala is on track for a rematch against Russian Ekaterina Alexandrova or a rubber match against Canadian Leylah Fernandez at the WTA 1000 Wuhan Open in China. World No. 18 Eala needs to get past a qualifier in her opening match likely on Monday before facing either No. 28 Alexandrova or No. 26 Fernandez who is of Filipino descent. Alexandrova and Fernandez were pitted against each other as the draw revealed on Saturday. Tournament No. 13 seed Eala battled Alexandrova at the Abu Dhabi Open quarterfinals where she fell to the latter, 3-6, 3-6, last February. Meanwhile, Eala first took on Fernandez at the Stuttgart Open round of 32, where she fell to the fellow lefty, 1-6, 4-6, last April. Eala exacted revenge on Fernandez at the Mubadala DC Open, dethroning the Fil-Canadian in the round of 16, 6–2, 7–6(1), and eventually ruled the tournament for her first WTA title last August. In the doubles of this Wuhan tournament, Eala will reunite with close pal Zeynep Sönmez. The Filipino-Turkish tandem will face the Ukrainian duo of Anhelina Kalinina and Dayana Yastremska in the first round. Eala and Sönmez last teamed up at the Madrid Open last May in Spain where they made a second round finish. Meanwhile, Eala is set to slip a spot to No. 19 in the WTA rankings on Monday. The live rankings on Sunday revealed Eala's slight descent from her career-high rank No. 18. Elise Mertens leaping from No. 19 to No. 14 bumped Eala down the rankings. Eala currently has 2,276 total ranking points.

YOUR NEWS, OUR NETWORK.

Do you have Great News you want to tell the world?

Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.